Dolly Khanna raises stake in multibagger smallcap stock to 3.33% in Q1. Do you own it?
ADVERTISEMENT Khanna raised her holding by 1.15 percentage points to 3.33% or 39,51,753 shares, up from 2.18% in the previous quarter.
Mangalore Chemicals has delivered stellar returns to investors. The stock has surged 148% in the past 12 months, 200% over two years, and over 770% in the last five years. It is also up 91% year-to-date. In Monday's trade, the stock rallied 7.8% to hit a new 52-week high of Rs 308.
Also Read: 7 Nifty500 stocks with highest dividend yields. Do you own any?
Separately, Khanna's name has also appeared in the latest shareholding pattern of small-cap Coffee Day Enterprises. She now holds 32.78 lakh shares or a 1.55% stake in the company as of the June 2025 quarter. Her name was absent in the March quarter filings, suggesting either a fresh investment or that her previous holding was below the 1% disclosure threshold.
Additionally, Khanna has increased her stake in Prakash Industries, another small-cap multibagger. Her holding rose by 0.2 percentage points to 2.27% or 40,56,674 shares in the company during Q1FY26.
ADVERTISEMENT As per Trendlyne data, Dolly Khanna currently holds 17 publicly listed stocks with a combined net worth of over Rs 488.8 crore. Her largest holding is in Zuari Industries, where she owns a 1.7% stake. Other notable investments include GHCL and Polyplex Corporation, with a 1.1% stake in each.
Also Read: Apollo Tyres, Brigade Enterprises among 10 small-cap stocks trading below industry PE; may rally up to 43%
ADVERTISEMENT Dolly Khanna, a Chennai-based prominent investor, is known for her lesser-known stock picks that often go on to outperform in the market. She has been investing in the stock market since 1996.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
ADVERTISEMENT
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
28 minutes ago
- The Hindu
From The Hindu, August 5, 1975: Direct dialling facility to benefit rural areas
New Delhi, Aug. 4: The Posts and Telegraphs Department is working on a rural dialling plan to benefit subscribers in small towns and villages. The plan is based on the traffic pattern obtaining in the rural areas. It will enable the subscribers in a district to have automatic dialling of calls between the towns and with the district headquarters. Sixty per cent of the calls in the rural areas have been found to be within a revenue district. Subscribers also put through more calls to the district headquarters rather than among themselves. Most of the calls are within a range of 50 kms. The rural dialling plan will provide quick communication in an economic way. Calls from places outside the district will be initially on a manual basis, but will become automatic in course of time. Several advantages are claimed for the plan from the pattern of traffic. The cost of handling a short distance trunk call is Rs. 3 on average, while the revenue earned remains around one rupee only. Hence it is more advantageous to provide STD service in a revenue district. Already exchanges of 100 or 50 lines are automatic whereas the trunk service is manual. Under the proposed scheme, there will be more customer satisfaction as 60 per cent to 70 per cent can dial themselves. The loss to the Department will also be reduced. The Telecommunication Research Centre (TRC) is fully equipped to meet the demand. It has already evolved a new technique in telephone exchanges or switching centres which will bring down the cost of the network.
Time of India
43 minutes ago
- Time of India
Eli Lilly opens tech, innovation centre in Hyd with plans to hire 1,500 in 2-3 yrs
1 2 Hyderabad: Pharma giant Eli Lilly and Company (India) opened its new technology and innovation centre in Hyderabad's Hitech City, spanning 2.2 lakh sq ft. The global capability centre (GCC) already houses around 100-120 employees and plans to accommodate around 1,500 employees by 2026-27. The facility, which also houses a nerve centre connecting all of Lilly's facilities globally, will serve as a strategic hub for advanced digital and technology capabilities and enhance efficiencies across its global operations. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad The Hyderabad site will focus on technologies such as artificial intelligence (AI), automation, cloud computing, and software product engineering to address global health challenges, Lilly said on Monday. Diogo Rau, executive vice president and chief information and digital officer, Eli Lilly and Co, said the new facility will not be a business processes or IT support hub but a centre of innovation. "This expansion brings together top talent in AI, data science, and engineering to build the digital foundation that will accelerate the discovery and delivery of innovative medicines with Hyderabad offering the perfect blend of deep technical expertise and collaboration," he said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 11 Foods That Help In Healing Knee Pain Naturally Undo Inaugurating the new GCC, Telangana chief minister Revanth Reddy said it attests to the growing stature of Hyderabad, which is home to nearly 2,000 life sciences companies and accounts for 40% of India's pharma production, as a global life sciences hub. He also outlined Telangana's ambitious economic goals of emerging as a $1 trillion economy in the next decade and contributing 10% to India's projected $30 trillion economy by 2047. Telangana IT & industries minister D Sridhar Babu said after adding around 70 GCCs in 2024-25, the state is now targeting attracting 100 GCCs in 2025-26. He said Hyderabad's Genome Valley and medtech parks have added 1.1 crore square feet of R&D and manufacturing space recently. He also pointed to Telangana's leadership in investment mobilisation with inflows of Rs 3.2 lakh crore in the past 19 months, surpassing states like Gujarat with 2.6 lakh crore and Tamil Nadu with Rs 2.1 lakh crore. He said the govt is also focused on digitally enabling patient records for over 40 million residents.
Time of India
an hour ago
- Time of India
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Why did Hims & Hers stock fall after earnings? Live Events Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Earnings beat estimates, but Wall Street stays cautious Is the GLP‑1 weight-loss business at risk? Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Hims keeps full-year guidance intact—thanks to international expansion Subscriber growth remains strong despite volatility What investors should watch going forward Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims still growing, but cracks are showing FAQs: (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever, raising questions about the future of itsDespite its rapid annual growth, Hims & Hers posted, missing the analyst estimate of. The real concern? Revenue dropped from, marking the first quarter-over-quarter decline since the company went stock currently trades at, regaining some ground after hitting an intraday low of. Despite opening at, it remains volatile, with an intraday high ofThe market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and were caught off guard, as the slowdown came amid soaring demand forlike semaglutide, a compound similar to the active ingredient in Wegovy and the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged:Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA.A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor:Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care company missed revenue estimates and saw its first-ever sequential drop in due to FDA scrutiny and legal issues around compounded semaglutide.
